Do Genetic Polymorphisms of B-cell CLL/lymphoma 2 Confer Susceptibility to Antituberculous Therapy Associated Drug Induced Liver Injury?
This study aimed to identify the relationship between B-cell CLL/lymphoma 2 (BCL2) polymorphisms and the susceptibility to antituberculous therapy associated drug induced liver injury (ATT-DILI). A total of 746 tuberculosis (TB) patients were enrolled in this study. Twenty-one selected single-nucleotide polymorphisms in BCL2 were analyzed by custom-by-design 2 × 48-Plex SNPscanTM kit. The allele and genotype frequencies between patients with or without ATT-DILI were compared with three different genetic models. A total of 727/746 participants were successfully genotyped, and 112 of them were diagnosed with ATT-DILI. A allele of rs8085707, G allele of rs76986960 and A allele of rs949037 conferred the increased risk of ATT-DILI with estimated odd ratios (ORs) of 2.181 (95% confidence interval [CI]: 1.345-3.536, p: 0.001), 1.983 (95% CI: 1.060-3.709, p: 0.029) and 1.390 (95% CI: 1.032-1.873, p: 0.03), respectively. While Bonferroni correction indicated that A allele of rs8085707 was a risk factor of ATT-DILI (p Bonferroni correction: 0.026). The additive model suggested that the patients with AA genotype of rs8085707 had significantly higher risk of ATT-DILI compared with those with GG genotype (p Bonferroni correction: 0.036). The influence of BCL2 polymorphisms on clinical characteristics (clinical symptoms, disease subtypes and laboratory indicators) was also identified. This study is the first to suggest an association between BCL2 polymorphisms and risk of ATT-DILI.